GlassScriptPhysician profile
Sandra J Ginsberg
NPI 1902823479
$3,351.50
in general payments reported to CMS, 2019-2025
37 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $344 · 2021: $492 · 2022: $594 · 2023: $685 · 2024: $486 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $708.31 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Incyte Corporation | $263.93 | 2019-2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $203.96 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.99 | 2019-2025 | Vpriv |
| Pharmacyclics LLC, An Abbvie Company | $154.72 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $141.64 | 2022-2025 | Calquence |
| Celgene Corporation | $136.96 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Beigene USA, INC. | $132.42 | 2020-2024 | Brukinsa |
| Seagen INC. | $130.73 | 2020-2023 | Tukysa |
| Astellas Pharma US INC | $125.28 | 2021-2024 | Padcev, Xtandi |
| Genzyme Corporation | $106.39 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $93.87 | 2019-2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $90.85 | 2019-2020 | |
| Daiichi Sankyo INC. | $77.67 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $65.79 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $63.80 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.71 | 2023 | |
| Abbvie INC. | $57.21 | 2024-2025 | |
| Beone Medicines USA, INC. | $50.83 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $46.77 | 2021-2024 | |
| Agios Pharmaceuticals, INC. | $46.17 | 2024 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $40.21 | 2019 | |
| Clovis Oncology, INC. | $38.85 | 2019-2020 | |
| Legend Biotech USA INC. | $31.29 | 2025 | Carvykti |
| Sobi, INC | $25.13 | 2023 | |
| Karyopharm Therapeutics INC. | $25.01 | 2022 | |
| Eusa Pharma (US) LLC | $24.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.54 | 2023 | |
| Genentech USA, INC. | $24.22 | 2023 | Columvi, Polivy, Lunsumio |
| Recordati_rare_diseases_inc. | $23.75 | 2023 | Sylvant |
| Sanofi Pasteur INC. | $23.61 | 2019 | |
| Apellis Pharmaceuticals, INC. | $23.57 | 2024 | Empaveli |
| Blueprint Medicines Corporation | $21.05 | 2022 | |
| Blue Earth Diagnostics | $20.86 | 2022 | |
| Pharmaessentia USA Corporation | $20.79 | 2023 | Besremi |
| Pharmacosmos Therapeutics INC. | $18.61 | 2022 | |
| Lilly USA, LLC | $16.07 | 2025 | Retevmo, Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ginsberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.